VEGFA and mucosal melanoma: A retrospective study evaluating the efficacy and safety of VEGF inhibitor, axitinib plus anti-PD-1 provides improved clinical benefits, with an ORR of 24.5%.630 The latest results of trials evaluating atezolizumab in combination with VEGF inhibitor, bevacizumab, for the use in patients with advanced mucosal melanoma shows promising benefit with an unconfirmed ORR of 42.9% in a relatively small population, and phase III trials with large population was needed to confirm the benefits.631